Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 255

1.

PD-L1 expression in tumor cells and the immunologic milieu of bladder carcinomas: a pathologic review of 165 cases.

Davick JJ, Frierson HF, Smolkin M, Gru AA.

Hum Pathol. 2018 Jun 30. pii: S0046-8177(18)30242-9. doi: 10.1016/j.humpath.2018.06.028. [Epub ahead of print]

PMID:
29969606
2.

TGFβ signaling limits lineage plasticity in prostate cancer.

Hao Y, Bjerke GA, Pietrzak K, Melhuish TA, Han Y, Turner SD, Frierson HF Jr, Wotton D.

PLoS Genet. 2018 May 21;14(5):e1007409. doi: 10.1371/journal.pgen.1007409. eCollection 2018 May.

3.

The protein kinase C super-family member PKN is regulated by mTOR and influences differentiation during prostate cancer progression.

Yang CS, Melhuish TA, Spencer A, Ni L, Hao Y, Jividen K, Harris TE, Snow C, Frierson HF Jr, Wotton D, Paschal BM.

Prostate. 2017 Nov;77(15):1452-1467. doi: 10.1002/pros.23400. Epub 2017 Sep 6.

PMID:
28875501
4.

Fine Needle Aspiration Cytology of Diffuse-Type Tenosynovial Giant Cell Tumors.

Zhao Z, Paquette C, Shah AA, Atkins KA, Frierson HF.

Acta Cytol. 2017;61(2):160-164. doi: 10.1159/000457828. Epub 2017 Mar 22.

PMID:
28324880
5.

Checkpoint Kinase 2 Negatively Regulates Androgen Sensitivity and Prostate Cancer Cell Growth.

Ta HQ, Ivey ML, Frierson HF Jr, Conaway MR, Dziegielewski J, Larner JM, Gioeli D.

Cancer Res. 2015 Dec 1;75(23):5093-105. doi: 10.1158/0008-5472.CAN-15-0224. Epub 2015 Nov 16.

6.

Additive Effect of Zfhx3/Atbf1 and Pten Deletion on Mouse Prostatic Tumorigenesis.

Sun X, Xing C, Fu X, Li J, Zhang B, Frierson HF Jr, Dong JT.

J Genet Genomics. 2015 Jul 20;42(7):373-82. doi: 10.1016/j.jgg.2015.06.004. Epub 2015 Jun 25.

7.

Patient Mutation Directed shRNA Screen Uncovers Novel Bladder Tumor Growth Suppressors.

Hensel J, Duex JE, Owens C, Dancik GM, Edwards MG, Frierson HF, Theodorescu D.

Mol Cancer Res. 2015 Sep;13(9):1306-15. doi: 10.1158/1541-7786.MCR-15-0130. Epub 2015 Jun 15.

8.

Malignant gastrointestinal neuroectodermal tumour of the oesophagus with pulmonary metastasis and protracted survival.

Shah AA, Grosh WW, Frierson HF Jr.

Histopathology. 2015 Dec;67(6):927-30. doi: 10.1111/his.12740. Epub 2015 Jun 30. No abstract available.

PMID:
26018740
9.

Histologic and immunohistochemical assessment of penile carcinomas in a North American population.

Mentrikoski MJ, Stelow EB, Culp S, Frierson HF Jr, Cathro HP.

Am J Surg Pathol. 2014 Oct;38(10):1340-8. doi: 10.1097/PAS.0000000000000124.

PMID:
25210933
10.

Deletion of atbf1/zfhx3 in mouse prostate causes neoplastic lesions, likely by attenuation of membrane and secretory proteins and multiple signaling pathways.

Sun X, Fu X, Li J, Xing C, Frierson HF, Wu H, Ding X, Ju T, Cummings RD, Dong JT.

Neoplasia. 2014 May;16(5):377-89. doi: 10.1016/j.neo.2014.05.001. Epub 2014 Jun 14.

11.

Prostate cancer induced by loss of Apc is restrained by TGFβ signaling.

Bjerke GA, Pietrzak K, Melhuish TA, Frierson HF Jr, Paschal BM, Wotton D.

PLoS One. 2014 Mar 20;9(3):e92800. doi: 10.1371/journal.pone.0092800. eCollection 2014.

12.

Lymphoepithelioma-like carcinoma of the penis: association with human papilloma virus infection.

Mentrikoski MJ, Frierson HF Jr, Stelow EB, Cathro HP.

Histopathology. 2014 Jan;64(2):312-5. doi: 10.1111/his.12248. Epub 2013 Oct 9. No abstract available.

PMID:
24117963
13.

Convergent RANK- and c-Met-mediated signaling components predict survival of patients with prostate cancer: an interracial comparative study.

Hu P, Chung LW, Berel D, Frierson HF, Yang H, Liu C, Wang R, Li Q, Rogatko A, Zhau HE.

PLoS One. 2013 Sep 16;8(9):e73081. doi: 10.1371/journal.pone.0073081. eCollection 2013.

14.

Activation of Akt signaling in prostate induces a TGFβ-mediated restraint on cancer progression and metastasis.

Bjerke GA, Yang CS, Frierson HF, Paschal BM, Wotton D.

Oncogene. 2014 Jul 10;33(28):3660-7. doi: 10.1038/onc.2013.342. Epub 2013 Sep 2.

15.

Mutation signature of adenoid cystic carcinoma: evidence for transcriptional and epigenetic reprogramming.

Frierson HF Jr, Moskaluk CA.

J Clin Invest. 2013 Jul;123(7):2783-5. doi: 10.1172/JCI69070. Epub 2013 Jun 17.

16.

EWSR1 genetic rearrangements in salivary gland tumors: a specific and very common feature of hyalinizing clear cell carcinoma.

Shah AA, LeGallo RD, van Zante A, Frierson HF Jr, Mills SE, Berean KW, Mentrikoski MJ, Stelow EB.

Am J Surg Pathol. 2013 Apr;37(4):571-8. doi: 10.1097/PAS.0b013e3182772a15.

PMID:
23426124
17.

Tissue transglutaminase is a negative regulator of monomeric lacritin bioactivity.

Velez V F, Romano JA, McKown RL, Green K, Zhang L, Raab RW, Ryan DS, Hutnik CM, Frierson HF Jr, Laurie GW.

Invest Ophthalmol Vis Sci. 2013 Mar 1;54(3):2123-32. doi: 10.1167/iovs.12-11488.

18.

Loss of SPARC in bladder cancer enhances carcinogenesis and progression.

Said N, Frierson HF, Sanchez-Carbayo M, Brekken RA, Theodorescu D.

J Clin Invest. 2013 Feb;123(2):751-66. doi: 10.1172/JCI64782. Epub 2013 Jan 16. Erratum in: J Clin Invest. 2013 Sep 3;123(9):4089.

19.

Analysis of immunohistochemical stain usage in different pathology practice settings.

Shah AA, Frierson HF Jr, Cathro HP.

Am J Clin Pathol. 2012 Dec;138(6):831-6. doi: 10.1309/AJCPAGVTCKDXKK0X.

PMID:
23161717
20.

CD24 expression is important in male urothelial tumorigenesis and metastasis in mice and is androgen regulated.

Overdevest JB, Knubel KH, Duex JE, Thomas S, Nitz MD, Harding MA, Smith SC, Frierson HF, Conaway M, Theodorescu D.

Proc Natl Acad Sci U S A. 2012 Dec 18;109(51):E3588-96. doi: 10.1073/pnas.1113960109. Epub 2012 Sep 25.

21.

CD24 is an effector of HIF-1-driven primary tumor growth and metastasis.

Thomas S, Harding MA, Smith SC, Overdevest JB, Nitz MD, Frierson HF, Tomlins SA, Kristiansen G, Theodorescu D.

Cancer Res. 2012 Nov 1;72(21):5600-12. doi: 10.1158/0008-5472.CAN-11-3666. Epub 2012 Aug 27.

22.

Chimeric transcript generated by cis-splicing of adjacent genes regulates prostate cancer cell proliferation.

Zhang Y, Gong M, Yuan H, Park HG, Frierson HF, Li H.

Cancer Discov. 2012 Jul;2(7):598-607. doi: 10.1158/2159-8290.CD-12-0042. Epub 2012 Jun 19.

23.

Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation.

DeGraff DJ, Clark PE, Cates JM, Yamashita H, Robinson VL, Yu X, Smolkin ME, Chang SS, Cookson MS, Herrick MK, Shariat SF, Steinberg GD, Frierson HF, Wu XR, Theodorescu D, Matusik RJ.

PLoS One. 2012;7(5):e36669. doi: 10.1371/journal.pone.0036669. Epub 2012 May 10.

24.

Clinically significant copy number alterations and complex rearrangements of MYB and NFIB in head and neck adenoid cystic carcinoma.

Persson M, Andrén Y, Moskaluk CA, Frierson HF Jr, Cooke SL, Futreal PA, Kling T, Nelander S, Nordkvist A, Persson F, Stenman G.

Genes Chromosomes Cancer. 2012 Aug;51(8):805-17. doi: 10.1002/gcc.21965. Epub 2012 Apr 16.

PMID:
22505352
25.

Cyclin D1 and FADD as biomarkers in head and neck squamous cell carcinoma.

Rasamny JJ, Allak A, Krook KA, Jo VY, Policarpio-Nicolas ML, Sumner HM, Moskaluk CA, Frierson HF Jr, Jameson MJ.

Otolaryngol Head Neck Surg. 2012 Jun;146(6):923-31. doi: 10.1177/0194599811435052. Epub 2012 Feb 8.

PMID:
22323434
26.

Development and characterization of xenograft model systems for adenoid cystic carcinoma.

Moskaluk CA, Baras AS, Mancuso SA, Fan H, Davidson RJ, Dirks DC, Golden WL, Frierson HF Jr.

Lab Invest. 2011 Oct;91(10):1480-90. doi: 10.1038/labinvest.2011.105. Epub 2011 Jun 27.

27.

The MYB-NFIB gene fusion-a novel genetic link between adenoid cystic carcinoma and dermal cylindroma.

Fehr A, Kovács A, Löning T, Frierson H Jr, van den Oord J, Stenman G.

J Pathol. 2011 Jul;224(3):322-7. doi: 10.1002/path.2909. Epub 2011 May 27.

PMID:
21618541
28.

Analysis of MYB expression and MYB-NFIB gene fusions in adenoid cystic carcinoma and other salivary neoplasms.

Brill LB 2nd, Kanner WA, Fehr A, Andrén Y, Moskaluk CA, Löning T, Stenman G, Frierson HF Jr.

Mod Pathol. 2011 Sep;24(9):1169-76. doi: 10.1038/modpathol.2011.86. Epub 2011 May 13.

29.

Src and caveolin-1 reciprocally regulate metastasis via a common downstream signaling pathway in bladder cancer.

Thomas S, Overdevest JB, Nitz MD, Williams PD, Owens CR, Sanchez-Carbayo M, Frierson HF, Schwartz MA, Theodorescu D.

Cancer Res. 2011 Feb 1;71(3):832-41. doi: 10.1158/0008-5472.CAN-10-0730. Epub 2010 Dec 10.

30.

C-kit gene mutations in adenoid cystic carcinoma are rare.

Moskaluk CA, Frierson HF Jr, El-Naggar AK, Futreal PA.

Mod Pathol. 2010 Jun;23(6):905-6; author reply 906-7. doi: 10.1038/modpathol.2010.61. No abstract available.

31.

Rosai-Dorfman disease presenting as a pulmonary artery mass.

Walters DM, Dunnington GH, Dustin SM, Frierson HF, Peeler BB, Kozower BD, Ailawadi G, Jones DR, Lau CL.

Ann Thorac Surg. 2010 Jan;89(1):300-2. doi: 10.1016/j.athoracsur.2009.05.016.

PMID:
20103266
32.

Relationship between HLA class I antigen processing machinery component expression and the clinicopathologic characteristics of bladder carcinomas.

Cathro HP, Smolkin ME, Theodorescu D, Jo VY, Ferrone S, Frierson HF Jr.

Cancer Immunol Immunother. 2010 Mar;59(3):465-72. doi: 10.1007/s00262-009-0765-9. Epub 2009 Sep 16.

33.

Differential requirement for focal adhesion kinase signaling in cancer progression in the transgenic adenocarcinoma of mouse prostate model.

Slack-Davis JK, Hershey ED, Theodorescu D, Frierson HF, Parsons JT.

Mol Cancer Ther. 2009 Aug;8(8):2470-7. doi: 10.1158/1535-7163.MCT-09-0262. Epub 2009 Aug 11.

34.

The role of SPARC in the TRAMP model of prostate carcinogenesis and progression.

Said N, Frierson HF Jr, Chernauskas D, Conaway M, Motamed K, Theodorescu D.

Oncogene. 2009 Oct 1;28(39):3487-98. doi: 10.1038/onc.2009.205. Epub 2009 Jul 13.

PMID:
19597474
35.

PRK1 distribution in normal tissues and carcinomas: overexpression and activation in ovarian serous carcinoma.

Galgano MT, Conaway M, Spencer AM, Paschal BM, Frierson HF Jr.

Hum Pathol. 2009 Oct;40(10):1434-40. doi: 10.1016/j.humpath.2009.02.008. Epub 2009 May 7.

36.

Histone acetyltransferase Hbo1: catalytic activity, cellular abundance, and links to primary cancers.

Iizuka M, Takahashi Y, Mizzen CA, Cook RG, Fujita M, Allis CD, Frierson HF Jr, Fukusato T, Smith MM.

Gene. 2009 May 1;436(1-2):108-14. doi: 10.1016/j.gene.2009.01.020. Epub 2009 Feb 10.

37.

Src phosphorylation of RhoGDI2 regulates its metastasis suppressor function.

Wu Y, Moissoglu K, Wang H, Wang X, Frierson HF, Schwartz MA, Theodorescu D.

Proc Natl Acad Sci U S A. 2009 Apr 7;106(14):5807-12. doi: 10.1073/pnas.0810094106. Epub 2009 Mar 25.

38.

Human papillomavirus profile of women in Belize City, Belize: correlation with cervical cytopathologic findings.

Cathro HP, Loya T, Dominguez F, Howe SL, Howell R, Orndorff K, Moreno J, Mendez E, Fung PC, Beer NL, Allen P, Sosa AM, Gurka KK, Stoler MH, Frierson HF Jr.

Hum Pathol. 2009 Jul;40(7):942-9. doi: 10.1016/j.humpath.2008.12.015. Epub 2009 Mar 18.

PMID:
19299000
39.

Profiling bladder cancer organ site-specific metastasis identifies LAMC2 as a novel biomarker of hematogenous dissemination.

Smith SC, Nicholson B, Nitz M, Frierson HF Jr, Smolkin M, Hampton G, El-Rifai W, Theodorescu D.

Am J Pathol. 2009 Feb;174(2):371-9. doi: 10.2353/ajpath.2009.080538. Epub 2009 Jan 15.

40.

Integrin agonists as adjuvants in chemotherapy for melanoma.

Schwartz MA, McRoberts K, Coyner M, Andarawewa KL, Frierson HF Jr, Sanders JM, Swenson S, Markland F, Conaway MR, Theodorescu D.

Clin Cancer Res. 2008 Oct 1;14(19):6193-7. doi: 10.1158/1078-0432.CCR-08-1285.

41.

Adenosquamous carcinoma of extrahepatic bile duct: clinicopathologic study of 12 cases.

Hong SM, Kim MJ, Jang KT, Yoon GS, Cho H, Frierson HF, Yu E.

Int J Clin Exp Pathol. 2008 Jan 1;1(2):147-56.

42.

Comprehensive evaluation of CDX2 in invasive cervical adenocarcinomas: immunopositivity in the absence of overt colorectal morphology.

Sullivan LM, Smolkin ME, Frierson HF Jr, Galgano MT.

Am J Surg Pathol. 2008 Nov;32(11):1608-12. doi: 10.1097/PAS.0b013e31816d71c4.

PMID:
18753946
43.

Initial assessment of fine-needle aspiration specimens by telepathology: validation for use in pathology resident-faculty consultations.

Kerr SE, Bellizzi AM, Stelow EB, Frierson HF Jr, Policarpio-Nicolas ML.

Am J Clin Pathol. 2008 Sep;130(3):409-13. doi: 10.1309/NA7Y7THPTBF112A0.

PMID:
18701414
44.

Reassessment of the usefulness of frozen section analysis for hip and knee joint revisions.

Kanner WA, Saleh KJ, Frierson HF Jr.

Am J Clin Pathol. 2008 Sep;130(3):363-8. doi: 10.1309/YENJ9X317HDKEXMU.

PMID:
18701408
45.

Array comparative genomic hybridization analysis of olfactory neuroblastoma.

Guled M, Myllykangas S, Frierson HF Jr, Mills SE, Knuutila S, Stelow EB.

Mod Pathol. 2008 Jun;21(6):770-8. doi: 10.1038/modpathol.2008.57. Epub 2008 Apr 11.

46.

Phosphaturic mesenchymal tumor diagnosed by fine-needle aspiration and core biopsy: a case report and review of literature.

Policarpio-Nicolas ML, Abbott TE, Dalkin AC, Bennett-Wick J, Frierson HF Jr.

Diagn Cytopathol. 2008 Feb;36(2):115-9. doi: 10.1002/dc.20772. Review.

PMID:
18181193
47.

MMTV-EGF receptor transgene promotes preneoplastic conversion of multiple steroid hormone-responsive tissues.

Marozkina NV, Stiefel SM, Frierson HF Jr, Parsons SJ.

J Cell Biochem. 2008 Apr 15;103(6):2010-8.

PMID:
17960555
48.

Transcriptional oncogenomic hot spots in Barrett's adenocarcinomas: serial analysis of gene expression.

Razvi MH, Peng D, Dar AA, Powell SM, Frierson HF Jr, Moskaluk CA, Washington K, El-Rifai W.

Genes Chromosomes Cancer. 2007 Oct;46(10):914-28.

PMID:
17636545
49.
50.

Androgen-independent growth and tumorigenesis of prostate cancer cells are enhanced by the presence of PKA-differentiated neuroendocrine cells.

Deeble PD, Cox ME, Frierson HF Jr, Sikes RA, Palmer JB, Davidson RJ, Casarez EV, Amorino GP, Parsons SJ.

Cancer Res. 2007 Apr 15;67(8):3663-72.

Supplemental Content

Loading ...
Support Center